Adrian Franke to Dose-Response Relationship, Drug
This is a "connection" page, showing publications Adrian Franke has written about Dose-Response Relationship, Drug.
Connection Strength
0.183
-
Issell BF, Gotay CC, Pagano I, Franke AA. Using quality of life measures in a Phase I clinical trial of noni in patients with advanced cancer to select a Phase II dose. J Diet Suppl. 2009; 6(4):347-59.
Score: 0.066
-
Schneider LS, Hernandez G, Zhao L, Franke AA, Chen YL, Pawluczyk S, Mack WJ, Brinton RD. Safety and feasibility of estrogen receptor-? targeted phytoSERM formulation for menopausal symptoms: phase 1b/2a randomized clinical trial. Menopause. 2019 08; 26(8):874-884.
Score: 0.034
-
Le Marchand L, Yonemori K, White KK, Franke AA, Wilkens LR, Turesky RJ. Dose validation of PhIP hair level as a biomarker of heterocyclic aromatic amines exposure: a feeding study. Carcinogenesis. 2016 07; 37(7):685-691.
Score: 0.027
-
St John JA, Henderson VW, Hodis HN, Kono N, McCleary CA, Franke AA, Mack WJ. Associations between urine excretion of isoflavonoids and cognition in postmenopausal women in the Women's Isoflavone Soy Health clinical trial. J Am Geriatr Soc. 2014 Apr; 62(4):629-35.
Score: 0.024
-
Luo J, Gao YT, Chow WH, Shu XO, Li H, Yang G, Cai Q, Rothman N, Cai H, Shrubsole MJ, Franke AA, Zheng W, Dai Q. Urinary polyphenols and breast cancer risk: results from the Shanghai Women's Health Study. Breast Cancer Res Treat. 2010 Apr; 120(3):693-702.
Score: 0.017
-
Wood CE, Register TC, Franke AA, Anthony MS, Cline JM. Dietary soy isoflavones inhibit estrogen effects in the postmenopausal breast. Cancer Res. 2006 Jan 15; 66(2):1241-9.
Score: 0.013